Alnylam Pharmaceuticals (LTS:0HD2) Current Accrued Expense: $1,096 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HD2 Alnylam Pharmaceuticals Inc LTS:0HD2
65 GF Score
Price $252.94
GF Value $545.64
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Alnylam Pharmaceuticals Current Accrued Expense?

Alnylam Pharmaceuticals LTS:0HD2 +1.33% 65 Current Accrued Expense is $1,096 Mil as of Jun. 2026. GuruFocus rates LTS:0HD2 with a GF Score™ of 65/100 and a GF Value™ of $545.64 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Alnylam Pharmaceuticals's Current Accrued Expense for the quarter that ended in Jun. 2026 was $1,096 Mil.

Alnylam Pharmaceuticals's quarterly Current Accrued Expense increased from Dec. 2025 ($823 Mil) to Mar. 2026 ($946 Mil) and increased from Mar. 2026 ($946 Mil) to Jun. 2026 ($1,096 Mil).

Alnylam Pharmaceuticals's annual Current Accrued Expense declined from Dec. 2023 ($591 Mil) to Dec. 2024 ($579 Mil) but then increased from Dec. 2024 ($579 Mil) to Dec. 2025 ($823 Mil).

Alnylam Pharmaceuticals Current Accrued Expense Related Terms

Alnylam Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Alnylam Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alnylam Pharmaceuticals Current Accrued Expense Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 301.59 414.77 590.84 579.29 823.00

Alnylam Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 918.97 1,153.65 823.00 946.49 1,095.98
LTS:0HD2
65GF Score
Alnylam Pharmaceuticals Inc LTS:0HD2
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alnylam Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1,096 Mil mean?
Alnylam Pharmaceuticals (LTS:0HD2) has a Current Accrued Expense of $1,096 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Alnylam Pharmaceuticals and its competitors.
Is Alnylam Pharmaceuticals' Current Accrued Expense too high?
Alnylam Pharmaceuticals' current Current Accrued Expense is $1,096 Mil. Overall, Alnylam Pharmaceuticals has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Current Accrued Expense compare to RPRX and INSM?
Alnylam Pharmaceuticals' Current Accrued Expense of $1,096 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Alnylam Pharmaceuticals and its competitors. Alnylam Pharmaceuticals's current Current Accrued Expense is $1,096 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $545.64, compared to a current price of $252.94 — trading 53.6% below its estimated fair value. The current Current Accrued Expense is $1,096 Mil. Alnylam Pharmaceuticals' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Current Accrued Expense is $1,096 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?

Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued. The current stock price of $252.94 is trading 53.6% below its estimated GF Value™ of $545.64. GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for LTS:0HD2:

  • Current Accrued Expense: $1,096 Mil
  • GF Value™: $545.64 vs. price of $252.94 (53.6% below fair value)
  • GF Score™: 65/100 with 1 warning sign

No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alnylam Pharmaceuticals Business Description

Address 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
65GF Score

Get the complete analysis for LTS:0HD2

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$252.94
Price
$545.64
GF Value